Headquartered in Laval, QC Fiscal year ends December NYSE: BHC bauschhealth.com
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) is a global, diversified pharmaceutical company that develops, manufactures, and markets products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, and aesthetics. The company also holds a controlling interest in Bausch + Lomb Corporation, which operates global Vision Care, Surgical, and Pharmaceuticals businesses in the eye health space. Key products include Xifaxan in the Salix gastrointestinal franchise and the Thermage and Fraxel platforms in the Solta Medical aesthetics segment. Bausch Health operates across multiple geographies including the Americas, EMEA, and Asia Pacific, with international pharmaceutical operations spanning Latin America, Canada, and other markets. The company carries significant debt obligations and continues to evaluate strategic options for unlocking shareholder value, including maximizing the value of its Bausch Health and Bausch + Lomb assets. Updated
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
Dan Loeb of Third Point is a brilliant investor worth watching closely whenever the 13F filings roll in. He’s a billionaire activist investor who seems to know how to spot value in…
One insider scooped up many shares as Carl Icahn exited his stake in a medical device maker. There were other notable insider purchases too.
One of the best ways to spot a potential opportunity is by tracking insiders. After all, who knows the company better than an insider – the CEO, CFO, COO, officers, employees, and…
In the past week, a couple of gold-mining stocks attracted the attention of insider buyers. Billionaire hedge fund manager John Paulson was a huge insider buyer this past week.
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) is a global, diversified pharmaceutical company that develops, manufactures, and markets products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, and aesthetics.
24/7 Wall St.'s 12-month price target for BHC is $7.97, rated Buy. The Wall Street consensus target is $7.50. BHC price prediction →
